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ABSTRACT: 21 
Context: In humans, approximately 95% of circulating cortisol is bound to corticosteroid-binding 22 
globulin and albumin. It is only the free fraction that is biologically active and can activate signalling 23 
pathways via glucocorticoid hormone receptors in cells. Microdialysis is a well-established technique 24 
that enables the sampling of molecules in different compartments of the body, including extracellular 25 
fluid. This is the first study validating a rapid sampling microdialysis method measuring free cortisol 26 
in the subcutaneous and blood compartments of healthy volunteers.  27 
 28 
Methods: Healthy non-smoking volunteers (42 men; age 18-24 years; BMI 18-25 kg/m2) received 29 
placebo (saline), 250 g Synacthen or 1 mg dexamethasone with ten minutely sampling to measure 30 
total and free cortisol (subcutaneous, intravenous and saliva) for an hour before and 4 hours after 31 
administration.  32 
 33 
Results: Following stimulation by Synacthen, total serum cortisol and free cortisol in both 34 
compartments rose significantly, achieving and maintaining maximum levels between 2 and 3 hours 35 
following the stimulus. A decline in cortisol levels was evident after the administration of 36 
dexamethasone or placebo, but there was a clear pulsatile activity around lunchtime in the latter group 37 
which was prominent in the blood compartment (total and free cortisol). There was good correlation 38 
between serum total and free cortisol (SC and intravenous) in the Synacthen and dexamethasone 39 
groups with no significant delay (less than 5 minutes) between total and free cortisol. 40 
 41 
Conclusions: This seminal study demonstrated the dynamic responses of total blood cortisol and 42 
microdialysis derived free cortisol in blood, subcutaneous tissue and saliva in man.  43 
 44 
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INTRODUCTION: 46 
The hypothalamic-pituitary-adrenal (HPA) axis is the key neuroendocrine system responsible 47 
for maintaining homeostasis, mediating its effects through glucocorticoid hormones, corticosterone in 48 
the rodent and predominantly cortisol in man. Approximately 95% of circulating cortisol in man is 49 
inactive as it is bound to plasma proteins such as corticosteroid-binding globulin (CBG; also known 50 
as transcortin or SerpinA6 1) and albumin 2. Only the free fraction of the hormone is biologically 51 
active as it activates signalling pathways via binding to glucocorticoid hormone receptors in cells 52 
(Figure 1).   53 
Microdialysis is a well-established technique that enables the sampling of molecules in 54 
different compartments of the body, including extracellular fluid. Microdialysis has originally been 55 
developed for monitoring neurotransmitter levels in the brain of rodents and to study the effects of 56 
pharmacological interventions 3. However, in the early 1990s it was recognised that microdialysis 57 
could be applied to the measurement of glucocorticoid hormones in peripheral 4 and brain tissue 5 of 58 
the rat. This approach opened up the use of in vivo microdialysis for physiological studies with a 59 
particular focus on the stress hormone response 6. Importantly, microdialysis offers the significant 60 
advantage of directly measuring the active free component of glucocorticoid hormone, because the 61 
size of the membrane pores precludes diffusion of protein-bound glucocorticoid molecules. Using 62 
microdialysis in freely behaving rats and mice, Linthorst, Reul and colleagues showed stressor-63 
specific free corticosterone responses in the brain and elucidated the role of corticotropin-releasing 64 
factor (CRF), the glucocorticoid receptor (GR) and peripheral CBG in the regulation of free 65 
corticosterone levels 6–10. 66 
Recent studies have demonstrated the use of microdialysis to measure free cortisol in healthy 67 
controls and in patients undergoing medical and surgical stress (elective coronary artery bypass graft) 68 
11, in critically ill patients 12 including those in septic shock 13,14, and burns patients 15. Free cortisol 69 
was measured by equilibrium dialysis 11,12 or ultrafiltration 13 in blood, and by microdialysis in the 70 
subcutaneous adipose tissue 14, dermis 15 and brain 16. These studies however did not look in detail at 71 
dynamic changes in free cortisol levels. Conversely, in rats and mice, high-resolution microdialysis 72 
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has successfully been used to demonstrate circadian and ultradian free corticosterone rhythms and to 73 
capture dynamic free hormone responses to physiological and pharmacological challenges 6,9,17.  74 
Within this context, we aimed to translate this approach into high-resolution microdialysis in 75 
humans, which will ultimately enable us to study in detail dynamic free cortisol responses during 76 
health and disease. We aim to achieve this goal by validating a rapid sampling microdialysis method 77 
measuring free cortisol in the subcutaneous and blood compartments of healthy volunteers.  78 
Subcutaneous and blood free cortisol levels in dialysates were compared with total serum 79 
cortisol levels and free cortisol levels in saliva. The responsiveness of free and total cortisol in the 80 
different compartments, and their intricate relationship, were studied by stimulating cortisol release 81 
from the adrenal cortex with synthetic ACTH and by suppression of HPA axis activity by 82 
dexamethasone. The plasma responses of total cortisol to stimulation with synthetic ACTH or 83 
suppression by exogenous dexamethasone are well established and used as diagnostic tests in clinical 84 
practice, but there is little information about the effect of these compounds on free cortisol levels in 85 
extracellular fluid.   86 
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MATERIALS AND METHODS: 87 
PARTICIPANTS 88 
Non-smoking male volunteers (n=42) with normal BMI (18-25 kg/m2), aged 18 to 24 years, were 89 
recruited as per local ethical committee regulations (Application reference 08/H0101/16), in 90 
accordance with the Helsinki principles. All participants gave informed written consent before their 91 
participation in the study. They had no known, past or present, medical conditions, were on no regular 92 
pharmacological treatment including oral or parenteral corticosteroid use, and had no known drug 93 
allergies. 94 
 95 
MICRODIALYSIS PROCEDURE 96 
A. Subcutaneous microdialysis 97 
Subcutaneous (SC) microdialysis was performed using a sterile CMA 66 linear microdialysis catheter 98 
(Microdialysis AB, Stockholm, Sweden) with polyarylethersulphone membrane, length 30 mm, 99 
diameter 0.5 mm, molecular cut-off 20 kDa; polyurethane inlet and outlet tubes 400 and 100 mm, 100 
respectively, membrane diameter 0.5 mm. Commercially available sterile physiological perfusion 101 
fluid for peripheral tissue use (T1, M Dialysis AB formerly CMA Microdialysis, Stockholm, Sweden; 102 
sodium 147mmol/L, potassium 4mmol/L, calcium 2.3mmol/L, chloride 156mmol/L) was used to 103 
perfuse the SC catheter. 104 
 105 
B. Intravenous microdialysis 106 
Intravenous microdialysis was performed using a sterile MicroEye PME011 (Probe Scientific, 107 
Coventry, UK) concentric catheter (polymer membrane, length 15 mm, 0.2 mm diameter, molecular 108 
cut-off 9 kDa; PA6228 inlet and outlet tubes 400 mm and 200 mm, respectively). The intravenous 109 
catheter was perfused with a sterile mixture of 2 ml of 0.9% saline and 0.5 ml Arixtra (Fondaparinux 110 
Sodium, GlaxoSmithKline, Middlesex, UK) for anticoagulation. Prior to use, the outlet tube of each 111 
catheter was truncated to 100 mm (to match the length of SC catheter) with a sterile blade and its 112 
membrane was dipped in Arixtra to avoid microclots (as per manufacturer’s instructions). 113 
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C. Sampling 114 
A portable CMA 107 microdialysis pump with a sterile CMA 106 pump syringe (CMA Microdialysis 115 
AB, Stockholm, Sweden) at a flow rate of 2 µl/min was used for all experiments. Microdialysates 116 
were collected manually in polypropylene vials (300 µl; Royem Scientific Limited, Luton, UK) and 117 
stored at -80 until assay.  118 
  119 
COLLECTION OF BLOOD AND SALIVA SAMPLES 120 
Blood samples were collected as described previously by Henley et al 18, saliva samples were 121 
collected using Salivette® Cortisol synthetic swabs (Sarstedt, Nümbrecht, Germany) and stored at 122 
minus 80° C after centrifugation.  123 
 124 
EXPERIMENTAL DESIGN 125 
Participants arrived at the clinical research unit at least an hour in advance, and intravenous cannulae 126 
and microdialysis catheters were inserted and set up at least 45 minutes before the start of the 127 
experiment. The participants remained seated in a chair or reclining on a bed throughout the duration 128 
of sampling apart from during comfort breaks, when sampling was not interrupted. Standard meals 129 
were served at midday for all experiments. Subjects were allowed to carry out work-related activities 130 
on their personal computers. 131 
An intravenous cannula for blood sampling was inserted in the left ante-cubital fossa, and a SC 132 
microdialysis catheter was inserted subcutaneously in the middle part of lateral left upper arm 133 
(Experiment 1; Figures 2 and 3) or the lower anterior abdomen (Experiment 2; Figures 2 and 4). For 134 
Experiment 2, in addition to the SC microdialysis catheter, a concentric microdialysis catheter was 135 
inserted via an 18-G B-Braun intravenous catheter as per manufacturer’s recommendation in the right 136 
ante-cubital fossa (arm opposite to that used for blood sampling).  137 
Both serum and microdialysate samples were collected at ten-minutely intervals (Figures 3 and 138 
4). Two sets of experiments were conducted. The differences between the experiments include 139 
compartments studied using microdialysis and timing of the dialysates in relation to blood sampling. 140 
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In the first experiment, the site of the SC catheter was upper arm and dialysate sampling clock-period 141 
was 10:00 to 15:00 (n=6).  As microdialysate sampling is continuous, the sample reading was 142 
considered to represent the midpoint of a given sampling duration e.g. sample timing of 10:05 was for 143 
dialysate obtained between 10:00 and 10:10 and so on. In the second experiment, the site of the SC 144 
catheter was anterior abdomen, an additional intravenous microdialysis catheter was also inserted and 145 
dialysate sampling clock-period was 09:55 to 15:05 (n=8 participants). In both experiments, serum 146 
samples were collected at 10:00, 10:10 etc. The dialysate samples in the first experiment correspond 147 
to 10:05, 10:15 and so on, and in the second sample timings coincide with that of blood, exactly. 148 
Saliva samples were collected every thirty minutes during both sets of experiments starting at 10:00.  149 
In both experiments, one of the pharmacological agents [Synacthen 250 µg  (Ciba-Geigy, 150 
Basel, Switzerland), dexamethasone 1mg (1ml of 3ml saline mixed with 1ml (4mg/ml) 151 
dexamethasone, Organon laboratories, Cambridge UK), saline (Sodium chloride 0.9%, Pfizer Ltd, 152 
Kent UK)] was administered by 11:02 (Figure 2). 153 
 154 
ASSAYS  155 
Serum total cortisol concentrations were measured by electrochemiluminescent immunoassay (using a 156 
Cobas® e601 immunoassay analyser, Roche Diagnostics, Burgess Hill, UK). Intra-assay and inter-157 
assay precision for serum concentrations of 208, 561 and 1268 nmol/l had coefficients of variation 158 
(CV) of 1.3, 1.3, 1.1 % and 1.6, 1.5, 1.6 %, respectively. Dialysate samples were analysed using an 159 
ELISA assay for salivary (free) cortisol (IBL, Hamburg, Germany), which was optimised for the 160 
measurement of free cortisol in small dialysate volumes (15 µl instead of the recommended 20 µl). 161 
The small dialysate volumes allowed a singlicate measurement of each sample. The intra-assay and 162 
inter-assay precision for saliva concentrations of 7.45 and 64.58 nmol/l had CVs of 7.3 %, 3.1 % and 163 
8.8 %, 6.4 %, respectively. The cross reactivity of the assay with dexamethasone is stated by the 164 
manufacturer to be less than 1%. Saliva samples were prepared for analysis using a liquid-liquid 165 
extraction procedure with deuterated internal standards (d4-cortisol and d7-cortisone) before isocratic 166 
separation UPLC (Waters Acquity, BEH C18) and quantitation by MS-MS (Waters Premier XE). 167 
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Salivary cortisol and cortisone were analysed with an in-house assay developed by the Department of 168 
Clinical Biochemistry, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom 169 
using UPLC®-tandem mass spectrometry (Waters Acquity-Premier XE, Waters, Milford, MA 01757 170 
USA). The inter-assay CV for cortisol were 17.6 % and 9.9 % for 2 nmol/l and 46 nmol/l respectively, 171 
whereas those for cortisone were 6.7 % and 10.4 % for 4 nmol/l and 94 nmol/l respectively. The intra-172 
assay CV for cortisol were 18.3 % and 8.8 % for 2 nmol/l and 46 nmol/l respectively, whereas those 173 
for cortisone were 10.2 % and 8.0 % for 4 nmol/l and 94 nmol/l, respectively. 174 
 175 
STATISTICAL ANALYSES 176 
Analyses were performed with Stata 13 (Stata Corp, College Station, TX, USA). 177 
For graphical purposes, Figures 5 and 6 show data as mean ± SEM. As the data are not normally 178 
distributed, median values and ranges have been calculated and are presented in the text. The 179 
direction of change was assumed from serum to SC tissue, i.e. the pattern in the former would precede 180 
the latter; correlations among serum, SC, and saliva values were estimated using Spearman’s rank test 181 
for different time lags. In experiment 1, the range of time lag was from 5 to 125 minutes (i.e., values 182 
of serum cortisol at time zero were correlated with successive 10-minute values of SC free cortisol, 183 
from 5 to 125 minutes: due to the design of the experiment, there was a minimum of five minutes 184 
difference between successive serum total and SC free cortisol measurement). In experiment 2, the 185 
time lag range was from isotemporal measurements (lag zero) to lag 120 minutes. A limit of either 186 
120 (experiment 1) or 125 minutes (experiment 2) was decided as there were no further values after 187 
these time points.  188 
In order to further examine the relationship between serum total and SC free cortisol, data 189 
from the two individual experiments 1 and 2 were combined. Log transformation of this entire data 190 
set was carried out and smoothed time-wise mean of these log-transformed values were plotted using 191 
the R statistical software19. 192 
 193 
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RESULTS: 195 
Experiment 1: FREE CORTISOL IN THE SC TISSUE COMPARTMENT 196 
Figure 5 shows the expected circadian reduction in both total and SC free cortisol between 10:00 and 197 
11:00, before the administration of a pharmacological agent. Following stimulation by Synacthen, 198 
there is a marked and rapid rise in cortisol levels in all compartments. Peak levels are achieved 199 
between 2 and 3 hours post administration, with a gradual decline in the final hour of sampling. The 200 
median serum total cortisol level immediately before Synacthen was 321 nmol/l (range 188-773) and 201 
at peak was 973 nmol/l (range 778-1369) between 2 and 3 hours post injection. The median SC tissue 202 
free cortisol level pre-Synacthen was 11.5 nmol/l (range 2.3-38.5) and at peak was 67.4 nmol/l (18.7-203 
101.5) between 1 and 3.25 hours post injection.  204 
 Median serum total cortisol level pre dexamethasone (Figure 5) was 265.0 nmol/l (range 205 
169.0-434.0) and nadir level post dexamethasone was 66.0 nmol/l (range 34.0-78.0). For SC tissue 206 
free cortisol values, median pre dexamethasone level was 6.0 nmol/l (range 3.2-24.4) and nadir 2.0 207 
nmol/l (range 0.9-4.4). Continued decline in cortisol levels is evident after the administration of 208 
dexamethasone and placebo, but there was a clear pulsatile activity around lunchtime (midday) in the 209 
latter group. This pulse was prominent in serum but less so in SC tissue. Peak level of this pulse in 210 
serum cortisol was observed between 30 and 60 minutes after serving lunch and had returned to 211 
baseline (pre-lunch levels) latest by 2 hours. 212 
 Spearman correlation coefficients between serum and SC tissue measurements were 213 
calculated for the entire group in each treatment arm (Table 1.1); there was a significant correlation in 214 
both the treatment groups but not in the placebo group.  215 
 In order to address the existence of any delay between serum total and SC free cortisol levels 216 
a maximum delay of 125 minutes was considered in keeping with the sampling duration. Spearman 217 
correlation coefficient values were computed (Figure 7) at successive 10-minute time delay such that 218 
SC would lag behind serum from a minimum of 5 to maximum of 125 minutes. No clear trends in 219 
correlation coefficients were found for the placebo and dexamethasone-treated groups; conversely, 220 
correlation coefficients for ACTH shows a steady and significant decline with increasing lag times, 221 
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reflecting the profound increase and subsequent decrease to baseline levels in cortisol over the course 222 
of the experiment.  223 
 Correlations were calculated as in Figure 8 to investigate the relationship between SC tissue 224 
free cortisol and that of saliva free cortisol and saliva cortisone. For each of the three interventional 225 
groups, the median correlation between saliva cortisone and SC was better (+0.5, +0.83 and +0.9 for 226 
the Synacthen, dexamethasone and placebo groups, respectively) than that between saliva free cortisol 227 
and SC (+0.21, +0.6 and +0.4, respectively). At baseline, cortisone levels were higher than cortisol 228 
levels in saliva and the increase in the latter following Synacthen was more than that in the former. 229 
 230 
Experiment 2: FREE CORTISOL IN THE SC AND INTRAVENOUS COMPARTMENTS 231 
As in experiment 1, normal circadian fall was seen between 10:00 and 11:00 before the administration 232 
of a pharmacological agent (Figure 6). Following stimulation by Synacthen, total serum cortisol as 233 
well as free cortisol rose significantly, achieving and maintaining maximum levels between 2 and 3 234 
hours following the stimulus, with gradual decline in the final hour of sampling. The median serum 235 
total cortisol level immediately before Synacthen was 238.0 nmol/l (range 95.0-375.0) and at peak 236 
was 872.0 nmol/l (range 600.0-960.0) between 110 and 150 minutes post injection. The median free 237 
cortisol pre-Synacthen in SC tissue level was 6.1 nmol/l (range 0.6-16.75) and in intravenous 238 
compartment was 2.7 mmol/l (range 0.6-16.75) with peak of 44.55 nmol/l (28.8-95.7) between 120 239 
and 190 minutes post injection, in SC tissue, and 53.6 (range 29.3-101.7) between 120 and 160 240 
minutes, in intravenous compartment.  241 
  Median serum total cortisol level before the administration of dexamethasone was 265.0 242 
nmol/l (range 144.0-475.0) and nadir level post dexamethasone was 62.6 nmol/l (range 37.3-122.8). 243 
The median pre-dexamethasone level for SC tissue free cortisol was 5.5 nmol/l (range 3.2-11.8) and 244 
nadir 0.61 nmol/l (range 0.13-1.76) whereas those for intravenous free cortisol were 5.8 nmol/l (range 245 
1.7-9.3) and 0.5 nmol/l (range 0.3-1.3), respectively. As in the first experiment, the difference 246 
between placebo and dexamethasone groups was the peak around lunchtime (at midday) in all 247 
participants on a background of declining cortisol levels for the duration of sampling (Figure 6). As in 248 
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experiment 1, this activity was prominent in serum total cortisol levels and less so in SC free cortisol 249 
levels, but the intravenous free cortisol also showed the pulsatile rise.  250 
 Correlation coefficients were calculated for paired combinations of serum total, SC tissue free 251 
and intravenous free cortisol for each treatment group (Table 2.1). Similar to Experiment 1, whereas 252 
the correlations for the placebo group was not statistically significant, strong and significant 253 
correlations between cortisol in the different compartments were found in the stimulation and 254 
suppression groups.  255 
In order to investigate whether there exists a possible delay between serum and SC, serum and 256 
intravenous free levels, and between SC and intravenous free levels, correlations were computed for 257 
time-lag range of 0 to 120 minutes (Figure 9) at successive 10-minute time delay such that SC would 258 
lag behind serum from a minimum of 10 to maximum of 120 minutes. There was no significant trend 259 
in placebo and dexamethasone groups, with the best positive correlation at time zero. For Synacthen 260 
group, however there was a trend such that the median correlation value at 35 minutes (+0.52) was 261 
nearly equally inverse of that at 120 minutes (-0.58). This suggests that 120 minutes following a pulse 262 
of cortisol, SC value would be expected to decline further supporting the previous data.  263 
Correlation coefficients were calculated to examine the relationship between SC tissue free 264 
cortisol and saliva free cortisol and saliva cortisone (Figure 10). The strongest median correlation was 265 
found for the dexamethasone group (0.88), and it was true for both saliva fractions. The relationships 266 
for the remaining two treatment groups were weaker (0.3-0.5) for both saliva fractions. At baseline, 267 
cortisone levels were higher than cortisol levels in saliva and the increase in the latter following 268 
Synacthen was more than that in the former fraction. 269 
In order to further examine the relationship between serum total and SC free cortisol, data 270 
from the two experiments were combined. There was a strong evidence of effect of treatment in each 271 
of the three groups (Figure 11). In the dexamethasone group, the mean values from both the 272 
experiments continue to decline throughout the experiment like in the placebo group, apart from the 273 
mealtime peak in the latter group as previously mentioned. The mean peak values from the two 274 
experiments following Synacthen overlap suggesting maximum stimulation at two hours (regardless 275 
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of baseline levels). The mean nadir values from the two experiments remain separated in the 276 
dexamethasone group, however in the placebo groups there is a hint of an upward deflection in the 277 
second set of experiments.  278 
Cross-correlation plots of log transformed serum total and SC free cortisol for each individual 279 
in each of the treatment arms of the two studies are shown in Figure 12. This data confirmed previous 280 
analysis by demonstrating significant positive cross-correlation between serum and SC values across 281 
all participants in the Synacthen and dexamethasone groups. However, there was variability in the 282 
placebo group with poorer cross-correlation across the group, confirmed by the non-significant 283 
Spearman correlation coefficients calculated previously.  284 
 285 
 286 
 287 
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DISCUSSION:  289 
To our knowledge, this is the first study demonstrating the relationship between total cortisol 290 
in serum and free cortisol in three body compartments. We compared the dynamic responses of total 291 
blood cortisol and microdialysis derived free cortisol in blood, subcutaneous tissue and saliva in man. 292 
The only studies to have compared the dynamic responses of both blood and tissue glucocorticoid 293 
levels have been performed in the rat. A landmark series of studies of free corticosterone rhythms in 294 
different body compartments were performed using stress paradigm in which animals are forced to 295 
swim in water at 25°C. In these studies peak free hormone levels in the intravascular compartment, 296 
SC tissue 9 and in the brain (hippocampus) 6,17, were found 20 minutes later than the peak of total 297 
hormone in the plasma. 298 
Rather than using a stress manoeuvre, we used the Synacthen test, first described by Wood to 299 
ascertain adrenocortical reserve 20 and which can be performed at any time of the day 21. It has been 300 
shown to correlate well with responses to major surgical stress 11,22. There is a large literature relating 301 
to serum total cortisol levels at time 0 and 30 (and/or 60) minutes after Synacthen, but little is known 302 
about the effect on the pattern of free cortisol levels in a tissue, other than saliva 23.  303 
 There was good correlation between serum total and free cortisol (SC and intravenous) in the 304 
Synacthen and dexamethasone groups, with no discrimination between compartments. Forced swim 305 
stress in rodents showed a twenty-minute delay in free corticosterone rise in the hippocampus, blood 306 
and subcutaneous tissue, compared to total corticosterone in blood 6,9 most likely as a consequence of 307 
a stressor-specific rise in circulating CBG from the liver 9. This was not the case in our studies 308 
although delay of less than 5 minutes, if present, could not be ruled out due to the sampling frequency 309 
used in this study. The relationship between serum total and free cortisol (SC and intravenous) is not 310 
as strong in the placebo group, which is expected in a short sampling duration due to individually 311 
distinct secretory pulse patterns. With stimulation and suppression, the axis was entrained resulting in 312 
better correlation, whereas in the placebo group inter-individual variation in pulses is likely to have 313 
affected the correlation values. 314 
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 There was evidence of some secretory activity around noon in the placebo group – the only 315 
difference between placebo and dexamethasone groups. The clearly visible peak in serum was not 316 
discernible in the SC tissue in the majority of subjects, but was visible in the intravenous free fraction. 317 
This was especially true when the serum total cortisol peak was 400 nmol/l or more and, when serum 318 
total cortisol was at or above this level a change in SC levels was more noticeable. This may relate to 319 
the fact that this is the level of plasma cortisol at which CBG becomes saturated and any further 320 
change in cortisol results in a disproportionately large increase in free cortisol 24. Changes in the level 321 
of CBG or its affinity for cortisol via neutrophil elastase or changes in temperature can also alter free 322 
cortisol fractions 25. Change in albumin levels affecting free cortisol levels is relatively less strong 11. 323 
In our cohort of normal individuals, there is no reason to expect abnormalities of albumin or CBG 324 
levels or that there would be changes in body temperature known to markedly alter affinity of CBG 325 
for cortisol 24. Lunch was served to all individuals in the study groups at noon. 326 
The Synacthen studies produced a prompt and marked rise in plasma and free cortisol 327 
followed by decline in levels 120-125 minutes later in both the SC and intravenous compartments. 328 
The pharmacodynamics of Synacthen (1-24) are somewhat different to endogenous ACTH (1-39), 329 
with high levels evident up to 60 min following an intravenous injection of high dose Synacthen 26. 330 
Serum total cortisol levels post 250 g of Synacthen continue to increase at least until 75 minutes 26. 331 
Therefore, an endogenous cortisol pulse (of a shorter duration and consequent drop to lower levels) 332 
27,28, with no further hormone secretion would lead to drop in free cortisol levels in the SC tissue. This 333 
phenomenon may also be related to the saturation kinetics of CBG. Total and free cortisol remain in 334 
equilibrium in the serum, and free unbound cortisol will readily diffuse into tissues resulting in a rise 335 
in tissue levels soon after a pulse. With no further adrenal secretion of cortisol, if plasma cortisol 336 
levels dropped, CBG would no longer be saturated and there could be a concentration gradient of free 337 
cortisol from subcutaneous tissue to the blood compartment. The half-life of free cortisol in 338 
subcutaneous tissue is not known but could also contribute to this relationship.  339 
Exclusion of female participants, to avoid problems associated with menstrual cycle 340 
dependent changes in the levels of oestrogen and progesterone and their resulting effects on levels of 341 
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CBG and competition for binding to CBG, respectively, is a limitation of this study. We have 342 
attempted to exclude methodological factors that could influence our data. Both the free cortisol 343 
fractions for each individual were assayed in the same batch by the same method hence to minimise 344 
inaccuracies related to inter-assay variation. The membrane length of the SC was twice that of 345 
intravenous microdialysis probe, which could potentially result in differential recovery rates. In 346 
reality, the difference in recovery of cortisol from the two probes in in-vitro experiments was minimal 347 
(about 10%), not requiring an adjustment-factor for membrane length. To avoid discrepancies related 348 
to post prandial release of cortisol all of our participants received a standard lunch (commercially 349 
available ‘healthy’ range sandwich, orange juice and piece of fruit), providing consistency of food 350 
intake around the midday/meal related peak 29,30. 351 
The relationship between saliva cortisol and cortisone with SC free cortisol was not the 352 
primary focus of this study. Infrequent (half hourly) sampling and differential (non-identical) timing 353 
in relation to dialysates in the two experiments meant that pooling the data was of no benefit (unlike 354 
the pooling of serum total and SC free cortisol). Cortisone appeared to be a better correlate of SC free 355 
cortisol as described previously 23. 356 
In this study we have sought to ascertain how levels of free cortisol in both the blood and 357 
subcutaneous compartments of the body correlate with levels of total cortisol in the blood using both a 358 
stimulus with Synacthen and inhibition by dexamethasone. In both situations we found good 359 
correlation with total cortisol. We have found no significant delay between total levels in the blood 360 
and free levels in the blood and subcutaneous tissue although it was not possible to detect a delay of 361 
less than 5 minutes. Despite these good correlations, smaller endogenous pulses appeared to not be 362 
readily detected in the SC tissue. Investigating the relationship between serum total and SC free 363 
cortisol during undisturbed endogenous secretory activity will need further investigation. This study 364 
should now pave the way for investigating the levels of free cortisol certainly in subcutaneous and 365 
possibly other tissues and thereby truly understanding the role of cortisol in disease pathophysiology, 366 
particularly in conjunction with the previously reported ambulatory sampling device 31.  367 
 368 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 17 
  369 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 18 
ACKNOWLEDGEMENTS: This study has been funded by OPTIMI (EU-Grant FP7 248544). We 370 
thanks all healthy volunteer participants, and Dr W Woltersdorf (formerly of affiliation6) for his 371 
assistance with the use of chemical pathology laboratory.  372 
 373 
REFERENCES: 374 
1.  MILLS IH. TRANSPORT AND METABOLISM OF STEROIDS. Br Med Bull. 375 
1962;18(2):127-133. doi:10.1093/oxfordjournals.bmb.a069953 376 
2.  Murray D. Cortisol Binding To Plasma Proteins In Man In Health, Stress And At Death. J 377 
Endocrinol. 1967;39(4):571-591. doi:https://doi.org/10.1677/joe.0.0390571 378 
3.  Harp T. ZT. What did we learn from microdialysis? In: Handbook of Microdialysis: Methods, 379 
Application and Clinical Aspects. ; 2007. 380 
4.  Jasper M, Engeland W. Synchronous ultradian rhythms in adrenocortical secretion detected by 381 
microdialysis in awake rats. Am J Physiol. 1991. doi:10.1152/ajpregu.1991.261.5.R1257 382 
5.  Linthorst ACE, Flachskamm C, Holsboer F, Reul JMHM. Local administration of recombinant 383 
human interleukin-1β in the rat hippocampus increases serotonergic neurotransmission, 384 
hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology. 385 
1994. doi:10.1210/endo.135.2.7518383 386 
6.  Droste SK, De Groote L, Atkinson HC, Lightman SL, Reul JMHM, Linthorst ACE. 387 
Corticosterone levels in the brain show a distinct ultradian rhythm but a delayed response to 388 
forced swim stress. Endocrinology. 2008. doi:10.1210/en.2008-0103 389 
7.  Linthorst AC, Flachskamm C, Müller-Preuss P, Holsboer F, Reul JM. Effect of bacterial 390 
endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral 391 
activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci. 1995. 392 
8.  Linthorst AC, Flachskamm C, Hopkins SJ, et al. Long-term intracerebroventricular infusion of 393 
corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, 394 
and cytokine responses to a systemic inflammatory challenge. J Neurosci. 1997. 395 
9.  Qian X, Droste SK, Gutièrrez-Mecinas M, et al. A rapid release of corticosteroid-binding 396 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 19 
globulin from the liver restrains the glucocorticoid hormone response to acute stress. 397 
Endocrinology. 2011. doi:10.1210/en.2011-1008 398 
10.  Linthorst ACE, Peñalva RG, Flachskamm C, Holsboer F, Reul JMHM. Forced swim stress 399 
activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing 400 
hormone receptor-dependent mechanism. Eur J Neurosci. 2002. doi:10.1046/j.1460-401 
9568.2002.02400.x 402 
11.  Christ-Crain M, Jutla S, Widmer I, et al. Measurement of serum free cortisol shows discordant 403 
responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab. 2007;92(5):1729-404 
1735. doi:10.1210/jc.2006-2361 405 
12.  Hamrahian AH, Oseni TS, Arafah BM. Measurements of Serum Free Cortisol in Critically Ill 406 
Patients. N Engl J Med. 2004;350(16):1629-1638. doi:10.1056/NEJMoa020266 407 
13.  Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: A comparison of total and 408 
free plasma cortisol levels. J Clin Endocrinol Metab. 2006;91(1):105-114. 409 
doi:10.1210/jc.2005-0265 410 
14.  Vassiliadi DA, Ilias I, Tzanela M, et al. Interstitial cortisol obtained by microdialysis in 411 
mechanically ventilated septic patients: Correlations with total and free serum cortisol. J Crit 412 
Care. 2013. doi:10.1016/j.jcrc.2012.07.008 413 
15.  Cohen J, Deans R, Dalley A, Lipman J, Roberts MS, Venkatesh B. Measurement of tissue 414 
cortisol levels in patients with severe burns: a preliminary investigation. Crit Care. 2009. 415 
doi:10.1186/cc8184 416 
16.  Llompart-Pou JA, Pérez G, Raurich JM, et al. Loss of cortisol circadian rhythm in patients 417 
with traumatic brain injury: A microdialysis evaluation. Neurocrit Care. 2010. 418 
doi:10.1007/s12028-010-9399-1 419 
17.  Qian X, Droste SK, Lightman SL, Reul JMHM, Linthorst ACE. Circadian and ultradian 420 
rhythms of free glucocorticoid hormone are highly synchronized between the blood, the 421 
subcutaneous tissue, and the brain. Endocrinology. 2012. doi:10.1210/en.2012-1484 422 
18.  Henley DE, Leendertz JA, Russell GM, et al. Development of an automated blood sampling 423 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 20 
system for use in humans. J Med Eng Technol. 2009. doi:10.1080/03091900802185970 424 
19.  R Development Core Team . R: A Language and Environment for Statistical Computing. R 425 
Found Stat Comput. 2011. doi:10.1007/978-3-540-74686-7 426 
20.  Wood JB, James VHT, Frankland AW, Landon J. A RAPID TEST OF ADRENOCORTICAL 427 
FUNCTION. Lancet. 1965. doi:10.1016/S0140-6736(65)91526-6 428 
21.  McGill PE, Greig WR, Browning MC, Boyle JA. Plasma cortisol response to synacthen (beta-429 
1-24 Ciba) at different times of the day in patients with rheumatic diseases. Ann Rheum Dis. 430 
1967;26(2):123-126. doi:10.1136/ard.26.2.123 431 
22.  Widmer IE, Puder JJ, König C, et al. Cortisol response in relation to the severity of stress and 432 
illness. J Clin Endocrinol Metab. 2005;90(8):4579-4586. doi:10.1210/jc.2005-0354 433 
23.  Perogamvros I, Keevil BG, Ray DW, Trainer PJ. Salivary cortisone is a potential biomarker 434 
for serum free cortisol. J Clin Endocrinol Metab. 2010;95(11):4951-4958. 435 
doi:10.1210/jc.2010-1215 436 
24.  Cameron A, Henley D, Carrell R, Zhou A, Clarke A, Lightman S. Temperature-responsive 437 
release of cortisol from its binding globulin: A protein thermocouple. J Clin Endocrinol 438 
Metab. 2010. doi:10.1210/jc.2010-0942 439 
25.  Henley DE, Lightman SL. New insights into corticosteroid-binding globulin and 440 
glucocorticoid delivery. Neuroscience. 2011;180:1-8. doi:10.1016/j.neuroscience.2011.02.053 441 
26.  Alía P, Villabona C, Giménez O, Sospedra E, Soler J, Navarro MA. Profile, mean residence 442 
time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. 443 
Clin Endocrinol (Oxf). 2006;65(3):346-351. doi:10.1111/j.1365-2265.2006.02602.x 444 
27.  Veldhuis JD, Iranmanesh A, Lizarralde G, Johnson ML. Amplitude modulation of a burstlike 445 
mode of cortisol secretion subserves the circadian glucocorticoid rhythm. Am J Physiol. 1989. 446 
doi:10.1152/ajpendo.1989.257.1.E6 447 
28.  Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Amplitude, but not frequency, 448 
modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of 449 
the corticotropic axis in man. J Clin Endocrinol Metab. 1990. doi:10.1210/jcem-71-2-452 450 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 21 
29.  Stimson RH, Mohd-Shukri NA, Bolton JL, Andrew R, Reynolds RM, Walker BR. The 451 
postprandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation 452 
of adrenal and extra-adrenal cortisol production. J Clin Endocrinol Metab. 2014;99(1):160-453 
168. doi:10.1210/jc.2013-2307 454 
30.  Follenius M, Brandenberger G, Hietter B, Siméoni M, Reinhardt B. Diurnal cortisol peaks and 455 
their relationships to meals. J Clin Endocrinol Metab. 1982. doi:10.1210/jcem-55-4-757 456 
31.  Bhake RC, Leendertz JA, Linthorst ACE, Lightman SL. Automated 24-hours sampling of 457 
subcutaneous tissue free cortisol in humans. J Med Eng Technol. 2013. 458 
doi:10.3109/03091902.2013.773096 459 
 460 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 22 
TABLES AND FIGURES (Order of appearance within the text) 
 
 
 
 
This is an accepted authors draft of a paper published in Journal of Endocrinology and Metabolism 
Received 24/02/2019, Accepted 16/09/2019 
https://doi.org/10.1210/clinem/dgz002 
 
 23 
Figure 1. HYPOTHALAMIC-PITUITARY-ADRENAL-TISSUE AXIS. CRH from the hypothalamus stimulates ACTH release from the anterior pituitary resulting in 
cortisol production from the adrenal glands. Free cortisol thus released in the vascular system circulates as protein-bound (≈95%) and free (≈5%) fractions. Free hormone 
enters tissues, then into each cell where it binds its receptors (only glucocorticoid receptor GR represented in this figure). Hormone-receptor complex translocates from the 
cytoplasm to the nucleus, attaches to the glucocorticoid response element on the DNA triggering a cascade of events leading to hormone actions. Liver and adipose tissue 
predominantly convert circulating cortisone to active cortisol mediated by 11βHSD-1 while 11 βHSD-2 in the saliva & kidney converts cortisol into inactive cortisone. 
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Figure 2. DESIGN OF EXPERIMENTS 1 & 2. All catheter insertions were completed by 09:15. Sampling 
period of experiment 1 was 10:00 to 15:00 and 09:55 to 15:05 of experiment 2. Pharmacological agent, 
including saline/placebo, was injected by 11:02. Lunch was served at 12:00. 
 
 
 
 
 
 
 
 
 
 
Figure 3. PROTOCOL FOR EXPERIMENT 1.Ten minutely sampling was done from 10:00 to 15:00 manually 
for SC free cortisol and via automated sampling for blood. Pharmacological agent including saline/placebo was 
injected by 11:02. Lunch was served at 12:00. 
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Figure 4. PROTOCOL FOR EXPERIMENT 2. Ten minutely sampling was done from 09:55 to 15:05 manually 
for SC and IV free cortisol. Automated sampling of blood was done from 10:00 to 15:00. Pharmacological agent 
including saline/placebo was injected by 11:02. Lunch was served at 12:00. 
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Figure 5. GROUP (a,c,e – mean & SEM) and TYPICAL PROFILES WITHIN EACH GROUP (b,d,f) OF 
CORTISOL IN SERUM (Total), SC TISSUE (Free Fraction) & SALIVA (Free Fraction And Cortisone). 
Saline/placebo (a,b); 250 µg Synacthen (c,d) or 1mg dexamethasone (e,f) were administered by 11:02 hours. 
Sampling commenced at 10:00 with ten-minutely samples collected until 15:00. Saliva samples were collected 
every half hour starting at 10:00. Lunch was served at 12:00. 
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Figure 5. Results Of Experiment 1
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Figure 6. GROUP (a,c,e – mean & SEM) and TYPICAL PROFILES WITHIN EACH GROUP (b,d,f) OF 
CORTISOL IN SERUM (Total) and in SUBCUTANEOUS & INTRAVENOUS COMPARTMENTS (Free 
Fraction). Saline (a,b); 250 µg Synacthen (c,d) or 1mg Dexamethasone (e,f) were administered by 11:02 hours. 
Sampling commenced at 10:00 for serum, and at 09:55 for SC & IV with ten minutely samples being collected 
up to 15:00. Lunch was served at 12:00. 
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Table 1 CORRELATION BETWEEN SERUM AND SC CORTISOL AT TIME LAG 5 min (minimum time 
difference in this study). 
 
TABLE 1.1 CORRELATION BETWEEN SERUM AND SC CORTISOL AT TIME LAG 5 min 
TREATMENT (n=6) SPEARMAN CORRELATION 
COEFFICIENT 
p VALUE 
ACTH  0.75 <0.0001 
DEXAMETHASONE  0.68 <0.001 
PLACEBO  0.36 0.102 
 
 
Figure 7. SPEARMAN CORRELATION COEFFICIENT VALUES (Y AXIS) BETWEEN SERUM AND SC 
AT SUCCESSIVE 5-MINUTE TIME DELAY FROM 5 TO 125 MINUTES (X-AXIS). Squares indicate 
median values, vertical bars the interquartile range and dots are individual participant values. There is no 
significant trend in placebo and dexamethasone groups. 
 
 
 
Figure 8. SPEARMAN CORRELATION BETWEEN SC AND EITHER SALIVA FREE CORTISOL (f) OR 
CORTISONE (e) FOR EACH OF THE TREATMENT GROUPS (SynACTHen stimulation, DEXamethasone 
suppression or PLAcebo) at time lag of 5 minutes. Squares indicate median values, vertical bars the interquartile 
range and dots denote individual participant values. 
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Table 2 CORRELATION COEFFICIENTS AT TIME LAG 0. 
 
TABLE 2.1 CORRELATION COEFFICIENTS AT TIME LAG 0 
TREATMENT SERUM & SC Free SERUM & IV Free SC Free & IV Free 
ACTH  0.68 (p=0.001) 0.76 (p<0.001) 0.82 (p<0.001) 
DEXAMETHASONE 0.82 (p<0.001) 0.86 (p<0.001) 0.82 (p<0.001) 
PLACEBO 0.21 (p=0.322) 0.55 (p=0.008) 0.25 (p=0.309) 
    
Figure 9. SPEARMAN CORRELATION COEFFICIENT VALUES (Y AXIS) BETWEEN SERUM AND SC 
(bottom row); SERUM AND INTRAVENOUS (IV) free (middle row) AND, SC AND IV FREE (top row) 
CORTISOL AT SUCCESSIVE 10-MINUTE TIME DELAY FROM 0 TO 120 MINUTES (X-axis). 
SynACTHen group results are in the left column, DEXamethasone in the middle column, and PLAcebo in the 
right column. Squares indicate median values, vertical bars the interquartile range and dots are individual 
participant values. There is no significant trend in placebo and dexamethasone groups. For ACTH group, there 
is a trend such that the median correlation value at time 0 is nearly equally inverse at 120minutes. 
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Figure 10. SPEARMAN CORRELATION (Y-axis) BETWEEN SC AND EITHER SALIVA FREE 
CORTISOL (f) OR CORTISONE (e) PER TREATMENT GROUPS (ACTH stimulation, DEXamethasone 
suppression or PLAcebo) at isotemporal lag time. Squares indicate median values, vertical bars the interquartile 
range and dots denote individual participant values. 
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Figure 11. LOG TRANSFORMED MEAN VALUES OF SERUM TOTAL (UPPER PANEL) AND SC FREE 
CORTISOL (LOWER PANEL) FROM THE TWO PHARMACOLOGICAL MANIPULATION 
EXPERIMENTS. Bold line represents smoothed mean of all values and shaded area represents 95% confidence 
intervals. Dotted vertical lines indicate time of pharmacological intervention e.g. Synacthen, Dexamethasone or 
placebo. X-axis displays clock time. 
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Figure 12. CROSS-CORRELATION PLOTS OF LOG TRANSFORMED SERUM TOTAL AND SC FREE 
CORTISOL for representative individuals from the two experiments described in the text. ACF (autocorrelation 
factor) is on Y-axis, time lag on X-axis (lag 1=10min). Plots on the left are three typical individuals per 
treatment group from experiment one and those on the right from experiment two.. The top row=Synacthen 
group, middle row=dexamethasone group and the bottom row=the placebo group. Dotted lines indicate 
confidence intervals. Where vertical lines exceed dotted line (top two rows), there is a significant cross 
correlation. 
 
 
 
